Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEC89736 in Relapsed or Refractory B-cell Hematologic Malignancies
NCT04865458Phase 1Terminated
- Sponsor
- Sunshine Lake Pharma
- Start
- Apr 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HEC-89736 in B-cell hematologic malignancy, sponsored by Sunshine Lake Pharma. Primary endpoints: Dose-Limiting Toxicities at 28 days and Adverse Events. Started Apr 2021; status: terminated.
02
Drugs
HEC-89736
03
Conditions
B-cell hematologic malignancy
Beyond the preview
Go deeper on NCT04865458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04865458.